Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Mazdutide32 residuesHQGTFTSDYSKYLDEKKAKEFVEWLLEGGSSGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: IBI362, Xinermei, 信诺美
18.55% overall body weight loss at 60 weeks (20.08% in non-diabetic participants), and the curve was still dropping. Mazdutide is a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics and licensed to Eli Lilly. It earned NMPA approval in China in 2025 for weight management and type 2 diabetes. No Western regulatory path has been announced yet; a US Phase 2 trial (NCT06143956) is underway. The glucagon component adds thermogenic fat oxidation on top of GLP-1 appetite suppression, targeting both sides of the energy equation. Access outside China is currently limited to grey-market research compounds with no regulatory oversight.
20.08% mean body weight loss in non-diabetic participants at 60 weeks, with no plateau in sight. That number comes from GLORY-2 [1], the Phase 3 trial that earned mazdutide its NMPA approval in China. Mazdutide (IBI362, Xinermei) is an oxyntomodulin analogue that activates two receptors simultaneously. The GLP-1 side suppresses appetite through hypothalamic signaling and slows gastric emptying. The glucagon side drives hepatic fat oxidation and increases resting energy expenditure. Most GLP-1 drugs only cut calories in; mazdutide also increases calories out. The GLORY-1 trial tested 4 mg and 6 mg doses against placebo in Chinese adults with obesity. The 6 mg arm lost 14.01% of body weight at 48 weeks. GLORY-2 pushed to 9 mg and ran for 60 weeks. A separate head-to-head trial, DREAMS-3, compared mazdutide 6 mg against semaglutide 1 mg in type 2 diabetes. Mazdutide won the combined endpoint of HbA1c below 7% and at least 10% weight loss. A meta-analysis of 7 randomized controlled trials (n=680) confirmed the metabolic picture: 6.22% body weight reduction and 43.3% triglyceride drop versus placebo [2]. Blood pressure, uric acid, and lipid panels all improved in parallel. One honest limitation: every completed Phase 3 trial enrolled exclusively Chinese participants. Generalizability to non-Asian populations is unproven. Eli Lilly's US Phase 2 (NCT06143956) should start filling that gap, but results aren't expected soon. Western access today means grey-market research compounds with no quality guarantees.
Mazdutide is an oxyntomodulin analogue, meaning it mimics a gut hormone that naturally activates both GLP-1 and glucagon receptors. That dual signal is what separates it from single-target drugs like semaglutide. GLP-1 receptor activation does the familiar work. It suppresses appetite through hypothalamic signaling, slows gastric emptying to extend satiety after meals, and promotes glucose-dependent insulin secretion. These are the same pathways semaglutide and liraglutide use. The glucagon receptor adds a second mechanism. Glucagon activation increases hepatic energy expenditure and shifts the liver toward fat oxidation. This thermogenic effect means mazdutide doesn't just reduce food intake; it also burns more stored fuel at rest. In the GLORY trials, researchers observed concurrent improvements in triglycerides (43.3% reduction in meta-analysis), systolic blood pressure (7.57 mmHg drop), and uric acid alongside weight loss. One pharmacokinetic detail worth noting: mazdutide's half-life is highly variable. The Phase 1b trial (NCT04440345) measured a range of 6.1 to 28.1 days across subjects. Most clinical protocols use weekly dosing, which works for the majority. But that variability means some individuals may accumulate drug faster or slower than predicted, making the 4-week titration steps more than just a GI tolerance measure.
NMPA-approved (China) dual GLP-1/glucagon agonist with strong Phase 3 data. GLORY-2 showed 18.55% overall weight loss (20.08% non-diabetic subgroup) at week 60 with no plateau observed. Head-to-head DREAMS-3 Phase 3 showed superiority over semaglutide 1mg on combined glycemic+weight endpoint in T2D. Meta-analysis of 7 RCTs (n=680) confirms −6.22% body weight and −43.3% triglycerides vs placebo.
GLORY-2 Phase 3 (PMID 40421736, NEJM 2025): mazdutide 9mg once weekly, 60 weeks, n=462 (BMI ≥30); −18.55% weight overall, −20.08% non-diabetic subgroup vs −3.02% placebo; no weight-loss plateau at week 60
Trial population is exclusively Chinese; no Western (non-Asian) Phase 3 data yet; US Phase 2 (NCT06143956) ongoing under Lilly; half-life highly variable (6.1–28.1 days per Phase 1b); long-term data beyond 60 weeks limited; no head-to-head vs tirzepatide or retatrutide
Extremely limited Western community experience as of April 2026. Compound is China-approved only; grey-market supply is emerging but thin. The small number of Western users who have used it follow the clinical trial titration (3→6→9mg) directly. No independent community protocol consensus has formed.
Western community data is insufficient to establish alignment. The limited community use mirrors GLORY-2 clinical titration (3→6→9mg), reflecting adoption of trial data rather than independent community consensus. No community-originated dosing protocols have emerged.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 3mg | Weekly |
| Moderate | 6mg | Weekly |
| Aggressive | 9mg | Weekly |
The 100 mg vial format is unusual. Most peptides come in 5 mg or 10 mg vials; mazdutide's high concentration means reconstitution math is less forgiving. With 2 mL bacteriostatic water in a 100 mg vial, you get 50 mg/mL. That's 5x more concentrated than a typical peptide reconstitution. At that concentration, your doses look like this on a 100-unit insulin syringe: 3 mg = 0.06 mL = 6 units; 6 mg = 0.12 mL = 12 units; 9 mg = 0.18 mL = 18 units. Double-check your math every time. An accidental 60 units instead of 6 units would deliver 30 mg, ten times the starting dose. Titration pace matters more than most users expect. The 4-week hold at each dose level isn't just about GI tolerance. It lets the drug reach steady state given that variable 6 to 28 day half-life. Rushing the escalation guarantees worse nausea and unpredictable serum levels. Store lyophilized powder at 2 to 8 degrees Celsius. After reconstitution, refrigerate and use within 4 weeks. Discard if the solution looks cloudy or you see particles.
Mazdutide is used as continuous long-term therapy in clinical settings: no cycling protocol was studied or recommended in GLORY-1 or GLORY-2. Rapid weight regain is expected on discontinuation consistent with the GLP-1 drug class. Periodic pauses may be taken for monitoring investigations (e.g., calcitonin elevation, thyroid imaging, planned pregnancy) rather than for any pharmacological cycling rationale.
Or use the universal Peptide Calculator for any peptide.
Expected: ~12–14% weight loss at 48 weeks (GLORY-1 6mg arm); ~18–20% at 60 weeks (GLORY-2 9mg arm). Lipid, BP, and uric acid improvements concurrent.
Monitor: Weigh weekly. Lab panel at baseline, week 12, week 24, then every 12 weeks: lipids, LFTs, lipase/amylase, HbA1c, CBC, calcitonin. BP and HR at each visit.
Reconstitute: add 2 mL bacteriostatic water to the 100 mg lyophilized vial. Swirl gently until dissolved. Do not shake. Solution should be clear and colorless.
Calculate your dose: at 50 mg/mL concentration, 3 mg = 6 units, 6 mg = 12 units, 9 mg = 18 units on a standard 100-unit insulin syringe.
Draw up the calculated volume using a 29 to 31 gauge insulin syringe. Tap bubbles to the top and push them out before injecting.
Pinch a fold of skin, insert the needle at a 45 to 90 degree angle, and inject slowly.
Never inject into the same spot twice in a row.
Timing: once weekly, same day each week, at a consistent time. No strict meal timing requirement.
Escalate to 6 mg at week 5 if GI effects are tolerable. Hold at 6 mg through week 16 or longer if needed. Escalate to 9 mg at week 17 if 6 mg is well tolerated.
Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks. Do not freeze.
Triple GLP-1/GIP/glucagon agonist: overlapping GLP-1 and glucagon mechanisms with mazdutide. Additive GI toxicity; no safety or efficacy data for combination. Redundant receptor load with no proven benefit.
Do not combineDual GLP-1/GIP agonist: overlapping GLP-1 mechanism. High additive GI side effect risk; no safety or efficacy data for combination with mazdutide.
Do not combineGLP-1 agonist: same receptor target as mazdutide GLP-1 component. No benefit to combination; high additive nausea and vomiting risk.
Do not combineAlso a GLP-1/glucagon dual agonist: identical mechanism class as mazdutide. Redundant and additive receptor activation; avoid combination.
Do not combinePricing updated 2026-04-09
The most common reason participants dropped out of GLORY-2 was gastrointestinal toxicity at the 9 mg dose during escalation. Nausea, vomiting, and diarrhea are the dominant side effects, and they hit hardest during dose increases. In GLORY-1, GI adverse events occurred in roughly 50 to 60% of participants at the 6 mg dose. Most were graded mild to moderate. The Phase 1b trial [3] tested 9 mg and 10 mg doses in 36 subjects; GI events were the most frequent adverse reactions at both levels. Nausea typically peaks in the first 1 to 2 weeks at each new dose tier. Most users report improvement within 2 to 4 weeks of staying at the same dose. If nausea persists past 4 weeks at 6 mg, that's a signal to delay the 9 mg escalation. Decreased appetite is common and expected. It's part of the GLP-1 mechanism. But severe or prolonged anorexia at any dose warrants clinical attention, particularly in individuals already at lower BMI ranges. Constipation tends to replace diarrhea at maintenance doses. This shift from loose stools early to constipation later is consistent across the GLP-1 drug class and catches some users off guard. Heart rate increased by approximately 2.6 beats per minute in the GLORY-1 4 mg and 6 mg arms. That's a small change on average. Persistent tachycardia above 100 bpm should prompt evaluation. Like all GLP-1 receptor agonists, mazdutide carries a class warning for medullary thyroid carcinoma based on rodent C-cell tumor findings. No calcitonin signal above the 20 ng/L threshold was observed in any GLORY participant. Annual calcitonin monitoring is still recommended. Pancreatitis is a class risk. Lipase and amylase should be checked at baseline and week 12. Discontinue if levels rise alongside abdominal symptoms. The combination of raised lipase plus persistent abdominal pain is not something to wait out. Injection site reactions (redness, induration, bruising) occur at standard rates for subcutaneous peptides. Rotating injection sites between abdomen, thigh, and upper arm reduces frequency. Mazdutide is contraindicated in pregnancy and breastfeeding. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 should not use it. History of pancreatitis, severe gastroparesis, or known hypersensitivity to mazdutide or its excipients are also exclusions. If you're taking insulin or sulfonylureas, proactive dose reduction is required before starting. The combined glucose-lowering effect significantly raises hypoglycemia risk. Monitor fasting glucose weekly during the titration phase. When to stop: less than 5% weight loss by week 16, pancreatitis symptoms, calcitonin elevation with a thyroid nodule, GI effects preventing adequate nutrition, or pregnancy.
Verify Mazdutide dosing and safety with a second opinion
Mazdutide is NMPA-approved in China (Xinermei brand) but is not FDA-approved, not available via any licensed Western pharmacy, and not produced by US compounding pharmacies. All Western access is via grey-market research compound suppliers with no regulatory oversight over purity, concentration, or sterility. The 100mg/vial high-concentration format increases overdose risk if reconstitution math is incorrect.
| Test | When | Target |
|---|---|---|
| Body weight | Weekly | — |
| Lipid panel (LDL, HDL, total cholesterol, triglycerides, non-HDL) | Baseline, week 12, week 24, every 12 weeks thereafter | Triglycerides <150 mg/dL; LDL per cardiovascular risk tier |
| HbA1c and fasting glucose | Baseline, week 12, week 24, week 48 | — |
| Liver enzymes (ALT, AST) | Baseline, week 12, week 24 | ALT/AST <40 U/L (or <3x ULN) |
| Lipase and amylase | Baseline, week 12, then whenever abdominal symptoms occur | Lipase <3x ULN; no established threshold: trend + symptoms guide action |
| Serum calcitonin | Baseline, then annually | <20 ng/L; refer to endocrinology if elevated |
| Blood pressure (systolic and diastolic) | Each visit during escalation (at least every 4 weeks); every 8–12 weeks at maintenance | <130/80 mmHg |
| Heart rate | Each visit | 60–100 bpm; flag if sustained >100 bpm |
Primary efficacy measure; drives dose escalation decisions; assess response at weeks 12 and 24
Meta-analysis (PMID 38440786): −43.3% triglycerides, −16.8% total cholesterol vs baseline; confirm improvement; flag if triglycerides rising
Monitor glycemic effect; assess hypoglycemia risk if on concurrent antidiabetics; HbA1c improved ~1.5–2.0pp in T2D trials
Pancreatitis and hepatic safety surveillance; flag and consider dose hold if ALT/AST >3x ULN
GLP-1 class pancreatitis risk; discontinue if elevated with concurrent abdominal symptoms
GLP-1 class MTC/thyroid C-cell class warning; no calcitonin signal observed in GLORY trials (no subject exceeded 20 ng/L threshold)
Meta-analysis: −7.57 mmHg systolic, −2.98 mmHg diastolic vs baseline; antihypertensive medication may require dose reduction
Mild tachycardia (+2.6 bpm) consistently noted in GLORY-1 at both 4mg and 6mg arms; monitor for persistent or symptomatic elevation
Titration initiation. Mild appetite suppression begins. GI side effects (nausea, diarrhea, decreased appetite) are most common in this phase as the body adjusts to dual-receptor activation.
Appetite suppression strengthens. Early weight loss of 3-5% is typical. GI side effects begin to ease for most users as dose escalates to 6mg.
Steady weight loss continues. Blood glucose and lipid markers start improving. Most users experience 6-10% body weight reduction during this window.
Escalation to full 9mg dose. Weight loss accelerates with the added thermogenic effect of glucagon activation. Phase 3 trials showed ~15% mean body weight loss by week 24.
Full dose maintenance. GLORY-2 trial data showed up to 20.1% body weight loss at 48 weeks. Metabolic markers continue improving. Weight loss rate plateaus as a new equilibrium is established.
Weeks 1 to 4 (3 mg, Titration Initiation): Appetite suppression kicks in within days of the first injection. GI effects are most common during this phase, especially nausea and loose stools after the first one or two doses. Don't expect visible weight change yet. The 3 mg dose is below the therapeutic threshold for most people; this phase is about letting your body adjust to dual-receptor activation. Very limited community data exists, but early user reports match the trial findings closely. Weeks 5 to 16 (6 mg, Escalation Phase): Appetite reduction gets noticeably stronger. The GLORY-1 trajectory puts you on track for roughly 10% weight loss by week 32 at this dose. Blood glucose and lipid markers start improving in this window. Nausea typically eases by weeks 8 to 10. Some users report constipation replacing the early diarrhea, and a mild heart rate bump of about 2.6 bpm was observed in GLORY-1. Insufficient Western community data to confirm these patterns independently. Weeks 17 to 32 (9 mg, Full Dose, Active Weight Loss): Weight loss accelerates as the glucagon thermogenic contribution ramps up at full dose. GLORY-2 shows a continued linear decline through this window without flattening. Blood pressure, lipid panels, and uric acid continue trending in the right direction. GI effects have largely resolved for most people by this point; constipation is the main remaining complaint. Monitor heart rate and blood pressure through this phase. Weeks 33 to 60 (9 mg maintenance, Maximum Efficacy Window): GLORY-2 results at week 60: 18.55% overall weight loss, 20.08% in the non-diabetic subgroup. The weight loss trajectory was still declining at the end of the trial. Triglycerides dropped 43.3% and systolic blood pressure fell 7.6 mmHg versus baseline in pooled data. Most users tolerate maintenance well. Annual calcitonin and thyroid monitoring is recommended at this stage.
Mild appetite suppression onset within days. GI side effects (nausea, diarrhea, decreased appetite) peak in this phase. Minimal weight change: insufficient time at therapeutic dose.
Very limited data. Users consistent with trial reports: appetite suppression begins within days; GI effects noticeable, especially after the first 1–2 injections.
Appetite suppression strengthens. GLORY-1 6mg arm trajectory: ~−10% weight by week 32. Blood glucose and lipid markers begin improving. GI side effects ease for most users after 2–4 weeks at each new dose.
Insufficient community data. Extrapolated from clinical reports: meaningful appetite reduction, early body composition changes, possible constipation replacing early-phase diarrhea.
Weight loss accelerates with glucagon thermogenic contribution added. GLORY-2 trajectory shows continued linear decline through this window. Cardiometabolic markers (BP, lipids, uric acid) continue improving.
No adequate Western community data for this phase.
GLORY-2: −18.55% overall, −20.08% non-diabetic subgroup at week 60. No plateau observed: weight loss trajectory still declining at week 60. GLORY-1 6mg: −14.01% at week 48. Triglycerides −43.3%, systolic BP −7.6 mmHg vs baseline (meta-analysis).
No adequate Western community data.
Source: Phase 1b trial (NCT04440345), ~7 days
Loading the interactive decay curve.
Mazdutide received NMPA approval in China in 2025 under the brand name Xinermei (信诺美) for chronic weight management and type 2 diabetes. It is not FDA-approved, not EMA-approved, and has no active regulatory submission outside China. Eli Lilly holds the ex-China commercial rights through a licensing agreement with Innovent Biologics. A US Phase 2 trial (NCT06143956) is currently recruiting, but no timeline for FDA submission has been disclosed. Western access is limited entirely to grey-market research compound suppliers. No US compounding pharmacy legally produces mazdutide. Products sold as "for research purposes only" carry no regulatory quality guarantee. Request HPLC certificates of analysis showing at least 98% purity before purchasing from any supplier. Mazdutide is not currently listed on WADA's prohibited substances list, but GLP-1 receptor agonists as a class may be subject to review. Athletes should verify current WADA guidance before use. This content is for informational and research purposes only. It is not medical advice. Consult a licensed healthcare provider before using any research compound.
Peptide Schedule Research TeamReviewed Apr 20267 Citations
